- Home
- USAU vs RXST Comparison
USAU vs RXST Comparison
Compare USAU & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | RXST |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.5M | 305.0M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | USAU | RXST |
|---|---|---|
| Price | $16.77 | $7.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 10 |
| Target Price | ★ $22.83 | $9.78 |
| AVG Volume (30 Days) | 301.7K | ★ 730.0K |
| Earning Date | 03-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $17,402,000.00 | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.03 | $5.90 |
| 52 Week High | $23.72 | $16.73 |
Technical Indicators
Market Signals| Indicator | USAU | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 54.32 |
| Support Level | $16.35 | $7.34 |
| Resistance Level | $19.20 | $9.11 |
| Average True Range (ATR) | 0.76 | 0.42 |
| MACD | 0.36 | 0.15 |
| Stochastic Oscillator | 86.77 | 81.64 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.